Abstract
Tisagenclecleucel is a gene therapy that contains manipulated T-lymphocytes of the same patient previously, in order to express, in their membrane, a chimeric antigenic receptor or CAR. This receptor allows the recognition of the CD19 lymphocyte antigen, both Malignant B lymphocytes as non-malignant
Keywords
Acute lymphoblastic leukemia; Tisagenclecleucel; CAR-T cells
Bibliographic citation
Programa d'harmonització farmacoterapèutica. Tisagenlecleucel per al tractament de la leucèmia limfoblàstica aguda. Barcelona: Servei Català de la Salut; 2019.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/4274This item appears in following collections
The following license files are associated with this item: